These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. New partnership calls for clinical testing of two fusion inhibitors. Slovick J Posit Living; 1999 Aug; 8(7):15, 62. PubMed ID: 12492078 [No Abstract] [Full Text] [Related]
11. Subcutaneous injection of the HIV-1 fusion inhibitor enfuvirtide (FUZEON) may result in soft-tissue accumulation of Tc-99m MDP. Pack LE; Zuckier LS Clin Nucl Med; 2012 Jan; 37(1):100-1. PubMed ID: 22157043 [No Abstract] [Full Text] [Related]
12. An open-label safety study of enfuvirtide injection with a needle-free injection device or needle/syringe: the Biojector 2000 Open-label Safety Study (BOSS). Lalezari JP; Saag M; Walworth C; Larson P AIDS Res Hum Retroviruses; 2008 Jun; 24(6):805-13. PubMed ID: 18507525 [TBL] [Abstract][Full Text] [Related]
13. T-1249 development suspended. Huff B GMHC Treat Issues; 2003 Dec; 17(12):6. PubMed ID: 15011643 [No Abstract] [Full Text] [Related]
14. Enfuvirtide plasma levels and injection site reactions using a needle-free gas-powered injection system (Biojector). Harris M; Joy R; Larsen G; Valyi M; Walker E; Frick LW; Palmatier RM; Wring SA; Montaner JS AIDS; 2006 Mar; 20(5):719-23. PubMed ID: 16514302 [TBL] [Abstract][Full Text] [Related]
15. Enfuvirtide: patient acceptance and strategies for managing injection-site reactions. Rice C; Wilantewicz H AIDS Read; 2006 Sep; 16(9):470-4, 490-1. PubMed ID: 17024766 [TBL] [Abstract][Full Text] [Related]
17. Enfuvirtide: a new class of antiretroviral therapy for HIV infection. Leao JC; Frezzini C; Porter S Oral Dis; 2004 Nov; 10(6):327-9. PubMed ID: 15533206 [TBL] [Abstract][Full Text] [Related]
18. A novel form of amyloid deposited at the site of enfuvirtide injection. Naujokas A; Vidal CI; Mercer SE; Harp J; Kurtin PJ; Fox LP; Thompson MM J Cutan Pathol; 2012 Feb; 39(2):220-1; quiz 219. PubMed ID: 22264247 [No Abstract] [Full Text] [Related]
19. Pharmacokinetic bioequivalence of enfuvirtide using a needle-free device versus standard needle administration. True AL; Chiu YY; Demasi RA; Stout R; Patel I Pharmacotherapy; 2006 Dec; 26(12):1679-86. PubMed ID: 17125431 [TBL] [Abstract][Full Text] [Related]
20. The importance of sequencing in treatment options. Berger DS Posit Aware; 2001; 12(3):42-3. PubMed ID: 11686121 [No Abstract] [Full Text] [Related] [Next] [New Search]